News Releases
-
Oct 1, 2019
La Jolla, California, October 1, 2019 (PRNewswire) — Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the...
-
Sep 12, 2019
La Jolla, California, September 12, 2019 (PRNEWSWIRE) – Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), today announced that...
-
Aug 22, 2019
La Jolla, California, August 22, 2019 (PR NEWSWIRE) – Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs™) focused in rare muscle disorders and...
-
Apr 22, 2019Collaboration will pursue therapeutic targets focused on immunology and other indications
INDIANAPOLIS, IN, and LA JOLLA, CA — April 22, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Avidity Biosciences, Inc. today announced a global licensing and research collaboration...
-
Jan 3, 2019
LA JOLLA, CA — January 3, 2019 – Arthur A. Levin, Ph.D, executive vice president of research and development at Avidity Biosciences LLC, a biotechnology company advancing Antibody-...